VirBio
Develops immune-based medicines for chronic hepatitis delta, solid tumors, and HIV cure research.
$10.83
After-hours close0.00 (0.00%)
At close$10.83(−4.24%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 88.45%149.18M sharesInsiders 1.77%2.98M sharesOther 9.78%16.49M shares
Shares outstanding 168.65M · Float 128.76M · 76.4% free float
Institutions13F, as of Jun 30, 2026
245 holders · 149.18M shares · 33 new positions · 128 increased · 75 reduced · 48 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 20.68M | 12.26% | +2.68M | Aug 7, 2026 |
| Arch Venture Management, LLC | 12.69M | 7.53% | −222.5K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 11.50M | 6.82% | +2.28M | Aug 13, 2026 |
| SB Investment Advisers (UK) Ltd | 10.95M | 6.49% | 0 | Aug 14, 2026 |
| State Street Corp | 9.96M | 5.91% | +2.82M | Aug 7, 2026 |
| GSK PLC | 8.55M | 5.07% | 0 | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.39M | 3.79% | +1.01M | Aug 13, 2026 |
| Point72 Asset Management, L.P. | 5.67M | 3.36% | +3.71M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.80% | 14.83M | 13G | Apr 28, 2025 ↗ |
| Robert Nelsenincl. ARCH Venture Partners IX Overage, L.P., Clinton Bybee +5 more | 8.50% | 13.53M | 13D | Mar 3, 2026 ↗ |
| SB Investment Advisers (UK) Limited | 6.50% | 10.95M | 13G | May 15, 2026 ↗ |
| State Street Corporation | 5.90% | 9.96M | 13G | Aug 7, 2026 ↗ |
| Vanguard Portfolio Management | 5.79% | 9.26M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | 10 percent owner | 13.73M | 8.14% | Dec 3, 2025 |
| Vicki L. Sato | director | 1.08M | 0.64% | May 4, 2026 |
| Marianne de Backer | director, officer: President and CEO | 1.00M | 0.59% | Apr 30, 2026 |
| Robert J. More | director | 558.6K | 0.33% | Aug 12, 2026 |
| Mark Eisner | officer: EVP and Chief Medical Officer | 154.0K | 0.09% | Feb 26, 2026 |
| Jeffrey S. Hatfield | director | 39.8K | 0.02% | May 28, 2026 |
| Charles Elliott Sigal | director | 39.8K | 0.02% | May 28, 2026 |
| Norbert W. Bischofberger | director | 32.0K | 0.02% | May 28, 2026 |
| Ramy Farid | director | 32.0K | 0.02% | May 28, 2026 |
| Saira Ramasastry | director | 22.6K | 0.01% | Jun 2, 2025 |
8 ten-percent owners hold 29.65M shares by Form 4, outside the officers-and-directors figure above · 28 people have not refiled in the last 18 months (28.28M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 1, 2026 | Brent Sabatiniofficer: SVP, Chief Accounting Officer | Sale | 379 | $9.45 | 61,902 |
| Jun 1, 2026 | Janet Napolitanodirector | Sale | 3,200 | $9.45 | 21,216 |
| May 1, 2026 | Vicki L. Satodirector | Sale | 22,000 | $10.05 | 1,078,391 |
| Apr 6, 2026 | Marianne de Backerdirector, officer: President and CEO | Sale | 72,559 | $9.16 | 948,145 |
| Apr 1, 2026 | Vicki L. Satodirector | Sale | 22,000 | $9.07 | 1,100,391 |
| Mar 23, 2026 | Brent Sabatiniofficer: SVP, Chief Accounting Officer | Sale | 7,711 | $9.12 | 61,902 |
| Mar 2, 2026 | Vicki L. Satodirector | Sale · 2 lots | 22,000 | $9.51 | 1,122,391 |
| Feb 24, 2026 | Marianne de Backerdirector, officer: Chief Executive Officer | Sale | 14,762 | $9.53 | 1,020,704 |
| Feb 25, 2026 | Vanina de Verneuilofficer: EVP, General Counsel, Corp Sec | Sale | 13,700 | $9.82 | 112,982 |
| Feb 24, 2026 | Vanina de Verneuilofficer: EVP, General Counsel, Corp Sec | Sale | 3,117 | $9.53 | 126,682 |
CongressHouse and Senate disclosures
Not reported.